Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 329

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 329
---
&D”) portfolio management and (b) evaluates certain potential strategic transactions, chooses strategic transactions which it believes are in the best interest of the stockholders and takes action to oversee the Company’s negotiation of the terms and conditions of any such transaction and recommend any such transaction to the Board, and in each case performs such other functions as may be deemed necessary or convenient in carrying out the foregoing. The C&T Committee’s responsibilities include, among others, the following commercialization matters:

| • |     | providing strategic, directional and operational oversight and guidance to the Company regarding its commercial 
 activities and operations;                                                                                      |

| • |     | evaluating the alignment of the Company’s commercial and R&D programs and progress with the                                          
 Company’s strategic goals and objectives, taking into account the results of the Company’s pre-clinical studies and clinical trials; |

| • |     | overseeing periodic reviews of the Company’s product development pipeline, intellectual property portfolio                                        
 and commercial strategies, including a review and analysis of the progress and results of the Company’s pre-clinical studies and clinical trials; |

| • |     | overseeing key commercial and medical launch strategies prior to regulatory approval of new products or  
 indications as well as the R&D elements of the Company’s long-range plan and lifecycle management plans; |

| • |     | overseeing management on the scientific and R&D aspects of business development opportunities, including 
 licensing opportunities (both in-licensing and out-licensing), and M&A opportunities;                    |

| • |     | establishing, approving, modify, monitoring and directing the process and procedures related to the review and                                         
 evaluation of certain potential strategic transactions and determining whether to proceed with any such process, procedures, review or evaluation; and |

| • |     | determining on behalf of the Board and the Company whether a possible strategic transaction is advisable and is                                                                                                                                  
 fair to, and in the best interests of, the Company and its stockholders (or any subset of the stockholders of the Company that the C&T Committee determines to be appropriate), (ii) rejecting or approving a possible strategic transaction, or 
 recommending such rejection or approval to the Board, (iii) approving or recommending to the Board the consummation of a possible strategic transaction, and (iv) reviewing, evaluating and monitoring proceedings and activities of the         
 Company related to certain potential strategic transactions.                                                                                                                                                                                     |

Under its charter, the C&T Committee may form, and delegate authority to, subcommittees as appropriate. The C&T Committee reviews, discusses and assess